摘要
目的评价良性前列腺增生症3种药物治疗方案的成本、效果。方法将120例门诊良性前列腺增生症患者分为A、B、C组,分别给予爱普列特、非那雄胺、甲磺酸多沙坐嗪控释片观察疗效,并运用成本-效果法进行分析。结果3组成本分别为193.76、243.76、206.08元,有效率分别为77%、82%、90%(P>0.05),成本-效果比分别为2.52、2.97、2.30。结论C组方案治疗良性前列腺增生成本-效果比更优。
Objective To conduct cost-effectiveness analyses on 3 therapeutic schemes for benign prostatic hypertrophy. Methods A total of 120 cases with benign prostatic hypertrophy were ascribed to receive Epristeride （group A）, Proscar （group B） and Cardura XL （group C）, respectively, the curative effect were observed analyzed by cost-effectiveness method. Results The costs for 3 groups were 193.76 yuan,211.78 yuan and 206. 08 yuan, respectively, the effective rates were 77% , 82% and 90% （ P 〉 0. 05 ） , respectively, and the cost-effectiveness ratios were 2. 52,2. 97, and 2. 30, respectively. Conclusion Group C is superior interms of the cost-effectiveness ratio among the 3 regimes for benign prostatic hypertrophy.
出处
《中国现代药物应用》
2008年第2期17-18,共2页
Chinese Journal of Modern Drug Application
